Full Press Release Details
Plant Sciences, Inc. Locks Early CRISPR Intellectual Property Uses in
plant sciences entered in an exclusive license agreement with Regents of
the University of Minnesota covering certain uses of CRISPR technology
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--April 15, 2015--Regulatory News:
Cellectis plant sciences, Inc. (Paris:ALCLS), a Minnesota-based Company
focusing on developing healthier food products, has announced today that
it has signed an exclusive license agreement with the University of
Minnesota that grants Cellectis the worldwide rights to use the
technology covered by the patent rights of the family WO/2014/144155
entitled "Engineering Plant Genomes Using CRISPR/Cas Systems". In
addition to meganucleases and TALEN technology, this approach for
targeted modification of plant genomes was developed by the laboratory
of Professor Dan Voytas in the University of Minnesota.
The technology has demonstrated results in plant genome engineering and
adds to Cellectis plant sciences, Inc. strong intellectual property
rights in the gene editing field, in addition to meganuclease and TALENTM
"We are pleased to strengthen our collaboration with the University of
Minnesota and gain exclusive access to this technology that excites
academics and the industrial community for its simple access to design
new nucleases" commented Luc Mathis, Chief Executive Officer of
Cellectis plant sciences, Inc. "CRISPR technology is being rapidly
adopted by the life science community, and we are delighted to expand
our technology portfolio to it, opening new opportunities for the
commercial development of healthier food products."
Similarly to meganucleases, Zinc Fingers and TALEN , CRISPR technology
enables a number of useful tools to target specific loci in a genome
and/or modulate the expression of genes. The technology is based on
novel sequence-specific nucleases that can be cheaply engineered to
recognize any gene of interest in a genome. Application in plants,
similarly to the other gene editing technologies, could enable the
development of valuable crops.
About Cellectis Plant Sciences
Founded in 2010, Cellectis Plant Sciences is based in New Brighton,
Minnesota (United States). The company has developed a platform to
improve the quality of crops for the food and agriculture industries.
Cellectis Plant Sciences is involved in a network of collaborations that
include global companies (Bayer, Limagrain, Monsanto, and SESVanderhave,
among others), as well as leading healthcare (Mitsubishi Tanabe Pharma)
and food companies. Cellectis Plant Sciences is developing innovative
products with prominent partners in order to secure accessibility of its
products to consumers.
For further information please visit our website: www.cellectis-plantsciences.com
This press release contains forward-looking statements. You should not
place undue reliance on such statements because they are subject to
numerous risks and uncertainties relating to the company's operations
and business environment, all of which are difficult to predict and many
are beyond the company's control. Forward-looking statements include
information concerning the company's possible or assumed future results
of operations, including descriptions of its business strategy. These
statements often include words such as "anticipate," "believe," "can,"
"could," "estimate," "expect," "intend," "is designed to," "may,"
"might," "plan," "potential," "predict," "objective," "should," or
similar expressions. These factors are more fully discussed in the "Risk
Factors" section and elsewhere in the company's Registration Statement
on Form F-1, as amended (File No. 333-202205). You should understand
that these statements are not guarantees of performance or results. They
involve known and unknown risks, uncertainties and assumptions. Although
the company believes that these forward-looking statements are based on
reasonable assumptions, you should be aware that many factors could
affect its actual financial results or results of operations and could
cause actual results to differ materially from those in these
forward-looking statements. The company undertakes no obligation to
publicly update any forward-looking statements, whether as a result of
new information, future events or otherwise, except as required by law.
Jennifer Moore, 917-580-1088
Communications - New York City
Brad Miles, 646-513-3125
Harnest, 646-385-9008
VP Finance and Investor Relations